Cellyan Biotechnology Co., Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 12, 2026, reporting the resignations of its Chairman and an independent director, two new board appointments, and a legal name change by its controlling shareholder, all effective November 10-11, 2026.

Key Highlights

  • Chairman resigned: Mr. Lap Sun Wong stepped down as Chairman of the Board and as a director on November 10, 2026, leaving the Chairman position vacant.
  • Independent director resigned: Mr. Zhao Letao also resigned on November 10, 2026, vacating seats on the audit, compensation, and nominating and corporate governance committees, as well as the chairmanship of the compensation committee.
  • New executive director appointed: Ms. Shu Liu, the Company's sitting Chief Financial Officer, was appointed as an executive director with immediate effect on November 10, 2026.
  • New independent director appointed: Mr. Xiaohu Quan was appointed on November 11, 2026, and stepped into all committee roles previously held by Mr. Zhao, including chairman of the compensation committee.
  • Board now has five directors: Two executive directors (Mr. Chenyu Liang and Ms. Liu) and three independent directors (Ms. Jingyan Wu, Dr. Kam Leung Chan, and Mr. Quan), with no chairperson in place.
  • Controlling shareholder name change: Ms. Liying Wang, the Company's controlling shareholder, has legally changed her name to Aylin Ada under a Republic of Turkiye passport and a Name Equivalence Document dated November 6, 2026.

Board Composition Changes at Cellyan Biotechnology Following November 2026 Resignations

According to the filing, both resignations on November 10, 2026 were stated to be unrelated to any disagreement with the Company. Mr. Wong's departure as Chairman left the office vacant, with the filing noting that it "remains vacant unless otherwise resolved by the board of directors." Mr. Zhao's exit simultaneously removed him from three board committees and from the chairmanship of the compensation committee. Cellyan Biotechnology, incorporated in the Cayman Islands and headquartered in Kowloon, Hong Kong, operates in the biotechnology sector and files annual reports on Form 20-F with the SEC under Commission File Number 001-42468, listed on NASDAQ:HKPD.

To fill the resulting gaps, the Board made two appointments. Ms. Shu Liu, aged 30, has served as the Company's Chief Financial Officer since October 2025. According to the filing, her background includes roles as chief executive officer at Shenzhen Yingdatongli Investment Group Co., Ltd. from August 2024, and as an investment advisor at Guosen Securities Co., Ltd. from August 2023 to August 2024. She holds a Master's degree from Sun Yat-sen University and is qualified as an Intermediate Economist. Mr. Xiaohu Quan, aged 33, has served as a director of Jituo International Supply Chain Management Co., Ltd. since July 2026, and previously worked at Huawei Technologies Co., Ltd. as an overseas project supervisor from July 2019 to April 2025. He also holds a Master's degree from Sun Yat-sen University.

The filing states that the Board determined Mr. Quan qualifies as an "independent director" within the meaning of Nasdaq Listing Rule 5605(a)(2) and satisfies the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Separately, the Company disclosed that its controlling shareholder, formerly known as Liying Wang, legally changed her name to Aylin Ada. The filing states this name change "does not affect any rights, obligations, shareholding, beneficial ownership, interests, agreements or arrangements" relating to her or any entity she controls, including TUTU Business Services Limited.

What Was Disclosed

Cellyan Biotechnology's November 12, 2026 Form 6-K reported the resignations of its Chairman and one independent director, the appointment of two replacement directors with updated committee assignments, and the legal name change of the Company's controlling shareholder from Liying Wang to Aylin Ada.